Vericel (FRA:ATQP) Net Income (Continuing Operations): €20.8 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ATQP Vericel Corp FRA:ATQP
83 GF Score
Price €34.80
GF Value €46.09
! 4 Warning Signs
View Full Analysis

What is Vericel Net Income (Continuing Operations)?

Vericel FRA:ATQP -0.57% 83 Net Income (Continuing Operations) is €20.8 Mil as of Jun. 2026. GuruFocus rates FRA:ATQP with a GF Score™ of 83/100 and a GF Value™ of €46.09. The stock has 4 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Vericel's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was €1.9 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was €20.8 Mil.

Vericel  (FRA:ATQP) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Vericel Net Income (Continuing Operations) Related Terms

Vericel Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Vericel's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel Net Income (Continuing Operations) Chart

Vericel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.32 -15.90 -2.94 9.58 14.64

Vericel Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 4.34 19.97 -5.39 1.90
FRA:ATQP
83GF Score
Vericel Corp FRA:ATQP
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vericel Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €20.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €20.8 Mil mean?
Vericel (FRA:ATQP) has a Net Income (Continuing Operations) of €20.8 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Vericel and its competitors.
Is Vericel's Net Income (Continuing Operations) too high?
Vericel's current Net Income (Continuing Operations) is €20.8 Mil. Overall, Vericel has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Vericel's Net Income (Continuing Operations) compare to ADMA and KLRA?
Vericel's Net Income (Continuing Operations) of €20.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Vericel and its competitors. Vericel's current Net Income (Continuing Operations) is €20.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Vericel (FRA:ATQP) has a current Net Income (Continuing Operations) of €20.8 Mil. The stock's GF Value™ is €46.09, compared to a current price of €34.80 — trading 24.5% below its estimated fair value. The current Net Income (Continuing Operations) is €20.8 Mil. Vericel's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current Net Income (Continuing Operations) is €20.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €34.80 is trading 24.5% below its estimated GF Value™ of €46.09.

Key valuation signals for FRA:ATQP:

  • Net Income (Continuing Operations): €20.8 Mil
  • GF Value™: €46.09 vs. price of €34.80 (24.5% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care, operating primarily in the United States. Its main products include MACI, an autologous cultured chondrocyte implant on a porcine collagen membrane used to repair symptomatic cartilage defects of the knee in adults; Epicel, cultured epidermal autografts for patients with deep dermal or full-thickness burns; and NexoBrid, a bromelain-based enzymatic debridement agent for removing eschar in severe thermal burns. Vericel manufactures these autologous and biologic therapies at its own facilities and sells them through direct specialty sales forces to orthopedic surgeons, burn centers, hospitals, and surgical providers. Revenue is generated primarily from product sales in the U.S., supported by a single reportable segment covering research, development, manufacture, and distribution of its cellular therapies and specialty biologics.
83GF Score

Get the complete analysis for FRA:ATQP

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.80
Price
€46.09
GF Value